Therapeutic apheresis: An effective strategy for a combined targeting of circulating lipoproteins, inflammatory markers, PFAS, and microplastics in cardiometabolic and neurodegenerative disease?
Brain Health · 04.08.2026 · 1-13
DOI: 10.61373/bh026a.0024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Health, erschienen am 04.08.2026. Verfasst von Stefan R Bornstein und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS.
Abstract (Originalsprache)
Lipoprotein apheresis is a highly effective and well-established extracorporeal therapy designed to remove lipoproteins from human circulation on a large scale, particularly in patients with progressive cardiovascular diseases when conventional treatments fail to achieve adequate lipoprotein reduction. Beyond its lipid-lowering capabilities, therapeutic apheresis is used to eliminate pathogenic substances, such as autoantibodies and immune complexes, and to exert immunomodulatory effects. Recent research highlights its potential to reduce inflammatory mediators, making it a promising intervention for conditions associated with systemic inflammation, including neurodegenerative diseases and post-infectious syndromes. In addition to its established applications, therapeutic apheresis is being explored as a novel approach to address emerging environmental health challenges, such as the accumulation of per- and polyfluoroalkyl substances (PFAS) and micro- and nanoplastics (MNPs) in living organisms. These pollutants, which are increasingly pervasive in the environment, pose significant health risks, including metabolic disruption, carcinogenesis, and neuroinflammation. Recognizing the urgency of this issue, institutions such as the US Department of Health and Human Services have initiated research programs to develop methods to monitor and remove these contaminants from the human body. Here, our preliminary findings suggest that therapeutic apheresis may represent a promising approach for reducing environmental toxins, alongside its established role in lowering lipoproteins and inflammatory biomarkers, and warrants further systematic clinical investigation. This is based on the hypothesis that PFAS and MNPs form aggregates with lipids and proteins, suggesting that therapeutic apheresis could be an ideal method for clearance. In the initial results, we observed decreases in both PFAS and MNP levels in patient blood and sequestered plasma following double filtration plasmapheresis, although responses varied across individuals and analytes. Tissue and in vitro studies using imaging and functional bioassays may be suitable for demonstrating the potential of apheresis to remove PFAS and MNPs, as well as for assessing the impact of MNPs on cell viability, inflammation, and secretome profiles. These findings could serve as clinical surrogates to guide treatment frequency and evaluate the sustainability of therapeutic apheresis in mitigating health risks associated with environmental pollutants. While larger, well-designed clinical trials are needed to confirm these benefits, these early results could lay the groundwork for future research and clinical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
- School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King's College London, London, SE5 9NU UK.
- Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091 Zurich, Switzerland.
- Laboratory for Experimental Transfusion Medicine, Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
- Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, 01307 Dresden, Germany.
- Leibniz-Institut für Polymerforschung Dresden e.V., 01069 Dresden, Germany.
ORCID-Profile: Stefan R Bornstein, Waldemar Kanczkowski, Romy Walther, Romy Kronstein-Wiedemann, Dieter Fischer, Ioannis Oikonomakos, Roman N Rodionov, Yannick P Kok, Jordi Petriz, Yandy Marx Castillo-Aleman, Constanze Hantel, Felix Beuschlein, Giatgen A Spinas, Saravana K Ramasamy, Torsten Tonn, Mario Siervo, Ludwig Aigner, Henning Morawietz, Rinkoo Dalan, Kaomei Guan, Ma-Li Wong, Julio Licinio, Charlotte Steenblock
Förderung
- NIMH NIH HHS
Zitieren
APA
Bornstein, S. R., Kanczkowski, W., Walther, R., Kronstein-Wiedemann, R., Fischer, D., Oikonomakos, I., Rodionov, R. N., Tselmin, S., Kok, Y. P., Mavberg, P. A., Petriz, J., Ward, M. D., Castillo-Aleman, Y. M., Schuster, C., Petegorsky, M., Hantel, C., Beuschlein, F., Spinas, G. A., Wuestefeld, T., …, & Steenblock, C. (2026). Therapeutic apheresis: An effective strategy for a combined targeting of circulating lipoproteins, inflammatory markers, PFAS, and microplastics in cardiometabolic and neurodegenerative disease?. Brain Health, 1-13. https://doi.org/10.61373/bh026a.0024
Vancouver
Bornstein SR, Kanczkowski W, Walther R, Kronstein-Wiedemann R, Fischer D, Oikonomakos I, et al. Therapeutic apheresis: An effective strategy for a combined targeting of circulating lipoproteins, inflammatory markers, PFAS, and microplastics in cardiometabolic and neurodegenerative disease?. Brain Health. 2026:1-13. doi:10.61373/bh026a.0024
BibTeX
@article{Bornstein2026,
author = {Bornstein, Stefan R and Kanczkowski, Waldemar and Walther, Romy and Kronstein-Wiedemann, Romy and Fischer, Dieter and Oikonomakos, Ioannis and Rodionov, Roman N and Tselmin, Sergey and Kok, Yannick P and Mavberg, Philip A and Petriz, Jordi and Ward, Michael D and Castillo-Aleman, Yandy Marx and Schuster, Carlos and Petegorsky, Michael and Hantel, Constanze and Beuschlein, Felix and Spinas, Giatgen A and Wuestefeld, Torsten and Ramasamy, Saravana K and Ali, Yusuf and Sung, Joseph J Y and Tonn, Torsten and Siervo, Mario and Aswani, Andrew and Barbir, Mahmoud and Aigner, Ludwig and Morawietz, Henning and Dalan, Rinkoo and Guan, Kaomei and Wong, Ma-Li and Licinio, Julio and Steenblock, Charlotte},
title = {Therapeutic apheresis: An effective strategy for a combined targeting of circulating lipoproteins, inflammatory markers, PFAS, and microplastics in cardiometabolic and neurodegenerative disease?},
journal = {Brain Health},
year = {2026},
pages = {1--13},
doi = {10.61373/bh026a.0024}
}
EUVIMED